Pharmacokinetic variability of newer antiepileptic drugs: When is monitoring needed?

Clinical Pharmacokinetics

Volumn 45, Issue 11, 2006, Pages 1061-1075

  Johannessen, Svein I ^a,c   Tomson, Torbjörn ^b  

^a National Center for Epilepsy   (Norway)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c National Center for Epilepsy Sandvika   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; ANTICONVULSIVE AGENT; CARBAMAZEPINE; CIMETIDINE; DEXTROPROPOXYPHENE; DRUG METABOLITE; ENZYME INDUCING AGENT; ERYTHROMYCIN; ETIRACETAM; FELBAMATE; GABAPENTIN; LAMOTRIGINE; LICARBAZEPINE; NAPROXEN; ORAL CONTRACEPTIVE AGENT; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; PREGABALIN; PRIMIDONE; RIFAMPICIN; SALICYLIC ACID; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN; ZONISAMIDE;

DRUG ABSORPTION; DRUG ANTAGONISM; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INHIBITION; DRUG MECHANISM; DRUG METABOLISM; DRUG MONITORING; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG RESEARCH; FOOD DRUG INTERACTION; HUMAN; NONHUMAN; PREGNANCY; PRIORITY JOURNAL; REVIEW; SEIZURE; UNSPECIFIED SIDE EFFECT;

AMINES; ANTICONVULSANTS; CARBAMAZEPINE; CYCLOHEXANECARBOXYLIC ACIDS; DRUG INTERACTIONS; DRUG MONITORING; EPILEPSY; FRUCTOSE; GAMMA-AMINOBUTYRIC ACID; HUMANS; ISOXAZOLES; NIPECOTIC ACIDS; PHENYLCARBAMATES; PIRACETAM; PROPYLENE GLYCOLS; TRIAZINES; VIGABATRIN;

EID: 33750366552     PISSN: 03125963     EISSN: 03125963     Source Type: Journal    
DOI: 10.2165/00003088-200645110-00002     Document Type: Review

References (130)

1. Johannessen SI, Tomson T. General principles. Laboratory monitoring of antiepileptic drugs. In: Levy RM, Mattson RH, Meldrum BS, et al., editors. Antiepileptic drugs. 5th ed. Philadelphia (PA): Lippincott Williams & Wilkins, 2002: 103-11
2. Woo E, Chan YM, Yu YL, et al. If a well-stabilized epileptic patient has a subtherapeutic antiepileptic drug level, should the dose be increased? A randomized prospective study. Epilepsia 1988; 29: 129-39
3. Kozer E, Parvez S, Minassian BA, et al. How high can we go with phenytoin? Ther Drug Monit 2002; 24: 386-9
4. Perucca E. Is there a role for therapeutic drug monitoring of new anticonvulsants? Clin Pharmacokinet 2000; 38: 191-204
5. Kleckner NW, Glazewski JC, Chen CC, et al. Subtype-selective antagonism of N-methyl-D-aspartate receptors by felbamate: insights into the mechanism of action. J Pharmacol Exp Ther 1999; 289: 886-94
6. Schumaker RC, Fantel C, Kelton E, et al. Evaluation of the elimination of 14C felbamate in healthy men [abstract]. Epilepsia 1990; 31: 642
7. Palmer KJ, McTavish D. Felbamate: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in epilepsy. Drugs 1993; 45: 1041-65
8. Thompson CD, Gulden PH, Macdonald TL. Identification of modified atropaldehyde mercapturic acids in rat and human urine after felbamate administration. Chem Res Toxicol 1997; 10: 457-62
9. Thompson CD, Kinter MT, Macdonald TL. Synthesis and in vitro reactivity of 3-carbamoyl-2- phenylpropionaldehyde and 2-phenylpropenal: putative reactive metabolites of felbamate. Chem Res Toxicol 1996; 9: 1225-9
10. Kapetanovic IM, Torchin CD, Thompson CD, et al. Potentially reactive cyclic carbamate metabolite of the antiepileptic drug felbamate produced by human liver tissue in vitro. Drug Metab Dispos 1998; 26: 1089-95
11. Banfield CR, Zhu GR, Jen JF, et al. The effect of age on the apparent clearance of felbamate: a retrospective analysis using nonlinear mixed-effects modeling. Ther Drug Monit 1996; 18: 19-29
12. Richens A, Banfield CR, Salfi M, et al. Single and multiple dose pharmacokinetics of felbamate in the elderly. Br J Clin Pharmacol 1997; 44: 129-34
13. Glue P, Sulowicz W, Colucci R, et al. Single-dose pharmacokinetics of felbamate in patients with renal dysfunction. Br J Clin Pharmacol 1997; 44: 91-3
14. Wilensky AJ, Friel PN, Ojemann LM, et al. Pharmacokinetics of W-554 (ADD 03055) in epileptic patients. Epilepsia 1985; 26: 602-6
15. Wagner ML, Graves NM, Marienau K, et al. Discontinuation of phenytoin and carbamazepine in patients receiving felbamate. Epilepsia 1991; 32: 398-406
16. Leppik IE, Dreifuss FE, Pledger GW, et al. Felbamate for partial seizures: results of a controlled clinical trial. Neurology 1991; 41: 1785-9
17. Harden CL, Trifiletti R, Kutt H. Felbamate levels in patients with epilepsy. Epilepsia 1996; 37: 280-3
18. Johannessen SI, Battino D, Berry DJ, et al. Therapeutic drug monitoring of the newer antiepileptic drugs. Ther Drug Monit 2003; 25: 347-63
19. Johannessen SI. Can pharmacokinetic variability be controlled for the patient's benefit: the place of TDM for new AEDs. Ther Drug Monit 2005; 27: 710-3
20. Petroff OAC, Rothman DL, Behar KL, et al. The effect of gabapentin on brain gamma-aminobutyric acid in patients with epilepsy. Ann Neurol 1996; 39: 95-9
21. Goa KL, Sorkin EM. Gabapentin: a review of its pharmacological properties and clinical potential in epilepsy. Drugs 1993; 46: 409-27
22. Vollmer KO, Anhut H, Thomann P, et al. Pharmacokinetic model and absolute bioavailability of the new anticonvulsant gabapentin. In: Manelis J, Bental E, Loeber JN, et al., editors. Advances in epileptology. New York: Raven Press, 1989: 209-11
23. Vollmer KO, von Hodenberg A, Kölle EU. Pharmacokinetics and metabolism of gabapentin in rat, dog and man. Arzneim Forsch 1986; 36: 830-9
24. Turck D, Vollmer KO, Brockbrader H, et al. Dose-linearity of the new anticonvulsant gabapentin after multiple oral doses. Eur J Clin Pharmacol 1989; 36 Suppl.: A310
25. Stewart BH, Kugler AR, Thompson PR, et al. A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of lack of proportionality between increasing dose and drug levels in plasma. Pharm Res 1993; 10: 276-81
26. Besag FMC, Berry DJ, Aylett SA, et al. Serum gabapentin levels continue to increase with dose in the high-range in children and teenagers. Epilepsia 2000; 41 (Suppl. Florence): 147
27. Ouellet D, Bockbrader HN, Wesche DL, et al. Population pharmacokinetics of gabapentin in infants and children. Epilepsy Res 2001; 47: 229-41
28. Armijo JA, Pena MA, Adin J, et al. Association between patient age and gabapentin serum concentrations-to-dose ratio: a preliminary multivariate analysis. Ther Drug Monit 2004; 26: 633-7
29. McLean MJ. Gabapentin. Epilepsia 1995; 36 Suppl. 2: S57-86
30. Gatti G, Ferrari AR, Guerrini R, et al. Plasma gabapentin concentrations in children with epilepsy: influence of age, relationship with dosage, and preliminary observations on correlation with clinical response. Ther Drug Monit 2003; 25: 54-60
31. Lindberger M, Luhr O, Johannessen SI, et al. Serum concentration and effects of gabapentin and vigabatrin: observations from a dose titration study. Ther Drug Monit 2003; 4: 457-62
32. Xie X, Hagan RM. Cellular and molecular actions of lamotrigine: possible mechanisms of efficacy in bipolar disorder. Neuropsychobiology 1998; 38: 119-30
33. Fitton A, Goa K. Lamotrigine: an update of its pharmacology and therapeutic use in epilepsy. Drugs 1995; 50: 691-13
34. Dickens M, Chen C. Lamotrigine: chemistry, biotransformation, and pharmacokinetics. In: Levy RH, Mattson RH, Meldrum BS, et al., editors. Antiepileptic drugs. 5th ed. Philadelphia (PA): Lippincott Williams & Wilkins, 2002: 370-9
35. Hussein Z, Posner J. Population pharmacokinetics of lamotrigine monotherapy in patients with epilepsy: retrospective analysis of routine monitoring data. Br J Clin Pharmacol 1997; 43: 457-65
36. Öhman I, Vitols S, Tomson T. Lamotrigine in pregnancy: pharmacokinetics during delivery, in the neonate, and during lactation. Epilepsia 2000; 41: 709-13
37. Mikati MA, Fayad M, Koleilat M, et al. Efficacy, tolerability, and kinetics of lamotrigine in infants. J Pediatr 2002; 141: 31-5
38. Eriksson AS, Hoppu K, Nergåardh A, et al. Pharmacokinetic interactions between lamotrigine and other antiepileptic drugs in children with intractable epilepsy. Epilepsia 1996; 37: 769-73
39. Bartoli A, Guerrini R, Belmonte A, et al. The influence of dosage, age and comedication on steady-state plasma lamotrigine concentrations in epileptic children: a prospective study with preliminary assessment of correlations with clinical response. Ther Drug Monit 1997; 19: 252-60
40. Armijo JA, Btavo J, Cuadrado B, et al. Lamotrigine serum concentration-to-dose ratio: influence of age and concomitant antiepileptic drugs and dosage implications. Ther Drug Monit 1999; 21: 182-90
41. Chen C, Casale EJ, Duncan B, et al. Pharmacokinetics of lamotrigine in children in the absence of other antiepileptic drugs. Pharmacotherapy 1999; 19: 437-41
42. Battino D, Croci D, Granata T, et al. Single-dose pharmacokinetics of lamotrigine in children: influence of age and comedication. Ther Drug Monit 2001; 23: 217-22
43. Posner J, Holdich T, Crome P. Comparison of lamotrigine pharmacokinetics in young and elderly healthy volunteers. J Pharmacol Med 1991; 18: 19-29
44. Tran TA, Leppik IE, Blesi K, et al. Lamotrigine clearance during pregnancy. Neurology 2002; 59: 251-5
45. de Haan GJ, Edelbroek P, Segers J, et al. Gestation-induced changes in lamotrigine pharmacokinetics: a monotherapy study. Neurology 2004; 63: 571-3
46. Pennell PB, Newport DJ, Stowe ZN, et al. The impact of pregnancy and childbirth on the metabolism of lamotrigine. Neurology 2004; 62: 292-5
47. Fillastre JP, Taubert AM, Fialaire A, et al. Pharmacokinetics of lamotrigine in patients with renal impairment: influence of haemodialysis. Drug Exp Clin Res 1993; 19: 25-32
48. May TW, Rambeck B, Jurgens U. Influence of oxcarbazepine and methosuximide in lamotrigine concentrations in epileptic patients with or without valproic acid comedication: results of a retrospective study. Ther Drug Monit 1999; 21: 175-81
49. Wnuk W, Volanski A, Foletti G. Topiramate decreases lamotrigine concentrations [abstract]. Ther Drug Monit 1999; 21: 449
50. Ebert U, Thong NQ, Oertel R, et al. Effects of rifampicin and cimetidine on pharmacokinetics and pharmacodynamics of lamotrigine in healthy subjects. Eur J Clin Pharmacol 2000; 56: 299-304
51. Sabers A, Öhman I, Christensen J, et al. Oral contraceptives reduce lamotrigine plasma levels. Neurology 2003; 61: 570-1
52. Reimers A, Helde G, Brodtkorb E. Ethinyl estradiol, not progestogens, reduces lamotrigine serum concentrations. Epilepsia 2005 Sep; 46 (9): 1414-7
53. Sidhu J, Job S, Singh S, et al. The co-administration of lamotrigine and a combined oral contraceptive in healthy female subjects. Br J Clin Pharmacol 2006; 61: 191-9
54. Yuen AWC, Land G, Weatherley BC, et al. Sodium valproate acutely inhibits lamotrigine metabolism. Br J Clin Pharmacol 1992; 33: 511-3
55. Anderson GD, Yau MK, Gidal BE, et al. Bidirectional interaction of valproate and lamotrigine in healthy subjects. Clin Pharmacol Ther 1996; 60: 145-56
56. Kaufman KR, Gerner R. Lamotrigine toxicity secondary to setraline. Seizure 1998; 7: 163-5
57. Hirsch LJ, Weintraub AB, Buschbaum R, et al. Correlating lamotrigine serum concentrations with tolerability in patients with epilepsy. Neurology 2004; 63: 1022-6
58. Morris RG, Lee MY, Cleanthous X, et al. Long-term follow-up using a higher target range for lamotrigine monitoring. Ther Drug Monit 2004; 26: 626-32
59. Noyer M, Gillard M, Matagne A, et al. The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes. Eur J Pharmacol 1995; 286: 137-46
60. Klitgaard H. Levetiracetam: the preclinical profile of a new class of antiepileptic drugs. Epilepsia 2001; 42 Suppl. 4: 13-8
61. Bialer M, Johannessen SI, Kupferberg HJ, et al. Progress report on new antiepileptic drugs: a summary of the seventh Eilat conference (EILAT VII). Epilepsy Res 2004; 61: 1-48
62. Patsalos PN. Pharmacokinetics profile of levetiracetam: toward ideal characteristics. Pharmacol Ther 2000; 85: 77-85
63. Radtke RA. Pharmacokinetics of levetiracetam. Epilepsia 2001; 42 Suppl. 4: 24-7
64. May TW, Rambeck B, Jürgens U. Serum concentrations of levetiracetam in epileptic patients: the influence of dose and co-medication. Ther Drug Monit 2003; 25: 690-9
65. Pennell PB, Koganti A, Helmers S, et al. The impact of pregnancy and childbirth on the elimination of levetiractem [abstract]. Epilepsia 2005; 46 Suppl. 8: 89
66. French J. Use of levetiracetam in special populations. Epilepsia 2001; 42 Suppl. 4: 24-7
67. Contin M, Albani F, Riva R, et al. Levetiracetam therapeutic monitoring in patients with epilepsy and effect of concomitant antiepileptic drugs. Ther Drug Monit 2004; 26: 375-9
68. Kubova H, Mares P. Anticonvulsant action of oxcarbazepine, hydroxycarbazepine and carbamazepine against metrazol-induced motor seizures in developing rats. Epilepsia 1993; 34: 188-92
69. White HS. Comparative anticonvulsant and mechanistic profile of the established and newer antiepileptic drugs. Epilepsia 1999; 40 Suppl. 5: S2-S10
70. Calabresi P, De Murtas M, Stefani A, et al. Action of GP 47779 the active metabolite of oxcarbazepine, on the corticostriatal system: I. Modulation of corticostriatal synaptic transmission. Epilepsia 1995; 36: 990-6
71. Lloyd P, Flesch G, Dieterle W. Clinical pharmacology and pharmacokinetics of oxcarbazepine. Epilepsia 1994; 35 Suppl. 3: S10-3
72. Volosov A, Xiaodong S, Perucca E, et al. Enantioselective pharmacokinetics of 10-hydroxycarbazepine after oral administration of oxcarbazepine to healthy Chinese subjects. Clin Pharmacol Ther 1999; 66: 547-53
73. Volosov A, Bialer M, Xiaodong S, et al. Simultaneous stereoselective high-performance liquid chromatographic determination of 10-hydroxycarbazepine and its metabolite carbamazepine-10,11-trans-dihydrol in human urine. J Chromatog B Biomed Sci Appl 2000; 738: 419-25
74. Battino D, Estienne M, Avanzini G. Clinical pharmacokinetics of antiepileptic drugs in paediatric patients: Part II. Phenytoin, carbamazepine, sulthiame, lamotrigine, vigabatrin, oxcarbazepine and felbamate. Clin Pharmacokinet 1995; 29: 341-69
75. Wellington K, Goa KL. Oxcarbazepine: an update of its efficacy in the management of epilepsy. CNS Drugs 2001; 15: 137-63
76. Baruzzi A, Albani F, Riva R. Oxcarbazepine: pharmacokinetic interactions and their clinical relevance. Epilepsia 1994; 35 Suppl. 3: 9S-14S
77. Sallas WM, Milosavljev S, D'Souza J, et al. Pharmacokinetic drug interactions in children taking oxcarbazepine. Clin Pharmacol Ther 2003; 74: 138-49
78. Rey E, Bulteau CF, Motte J, et al. Oxcarbazepine pharmacokinetics and tolerability in children with inadequately controlled epilepsy. J Clin Pharmacol 2004; 44: 1290-300
79. Van Henningen PNM, Eve MD, Oosterhuis B, et al. The influence of age on the pharmacokinetics of the antiepileptic agent oxcarbazepine. Clin Pharmacol Ther 1991; 50: 410-9
80. Mazzucchelli I, Onat FY, Ozkara C, et al. Changes in disposition of oxcarbazepine and its metabolites during pregnancy and the puerperium. Epilepsia 2006; 47: 504-9
81. Rouan MC, Lecaillon JB, Godbillon J, et al. The effect of renal impairment on the pharmacokinetics of oxcarbazepine and its metabolites. Eur J Clin Pharmacol 1994; 47: 161-7
82. Tartara A, Galimberti CA, Manni R, et al. The pharmacokinetic profile of oxcarbazepine and its active metabolite 10-hydroxycarbazepien in normal subjects and in epileptic patients treated with phenobarbitone and valproic acid. Br J Clin Pharmacol 1993; 36: 366-8
83. McKee PJ, Blacklaw J, Forrest G, et al. A double-blind, placebo-controlled interaction study between oxcarbazepine and carbamazepine, sodium valproate and phenytoin in epileptic patients. Br J Clin Pharmacol 1994; 37: 27-32
84. Armijo JA, Vega-Gil N, Shushtarian M, et al. 10-Hydroxycarbazepine serum concentration-to-oxcarbazepine dose ratio: influence of age and concomitant antiepileptic drugs. Ther Drug Monit 2005; 27: 199-204
85. Keranen T, Jolkkonen J, Jensen PK, et al. Absence of interaction between oxcarbazepine and erythromycin. Acta Neurol Scand 1992; 86: 120-3
86. Morgensen PH, Jörgensen L, Boas J, et al. Effects of dextropropoxyphene on stead-state kinetics of oxcarbazepine and its metabolites. Acta Neurol Scand 1992; 85: 14-7
87. Baruzzi A, Albani F, Riva R. Oxcarbazepine: pharmacokinetic interactions and their clinical significance. Epilepsia 1994; 35 Suppl. 3: S14-9
88. Friis ML, Kristensen O, Boas J, et al. Therapeutic experiences with 947 epileptic out-patients in oxcarbazepine treatment. Acta Neurol Scand 1993; 87: 224-7
89. Van Parys JAP, Meinardi H. Survey of 260 patients treated with oxcarbazepine (Trileptal) on a named-patient basis. Epilepsy Res 1994; 19: 79-85
90. Borusiak P, Korn-Merker E, Holert N, et al. Oxcarbazepine in treatment of childhood epilepsy: a survey of 46 children and adolescents. J Epilepsy 1998; 11: 355-60
91. Ben-Menachem E. Pregabalin pharmacology and its relevance to clinical practice. Epilepsia 2004; 45 Suppl. 6: 13-8
92. Warner G, Figgitt DP. Pregabalin: as adjunctive treatment of partial seizures. CNS Drugs 2005; 19 (3): 265-72
93. Berry D, Millington C. Analysis of pregabalin at therapeutic concentrations in human plasma/serum by reversed-phased HPLC. Ther Drug Monit 2005; 27: 451-6
94. Czuczwar SJ, Patsalos PN. The new generation of GABA enhancers: potential in the treatment of epilepsy. CNS Drugs 2001; 15: 339-50
95. Wang X, Patsalos PN. The pharmacokinetic profile of tiagabine. Rev Contemp Pharmacother 2002; 12: 225-33
96. Gustavson LE, Boeller SW, Granneman GR, et al. A single-dose study to define tiagabine pharmacokinetics in pediatric patients with complex partial seizures. Neurology 1997; 48: 1032-7
97. Tomson T. Gender aspects of pharmacokinetics of new and old AEDs: pregnancy and breast-feeding. Ther Drug Monit 2005; 27: 718-21
98. Lau AH, Gustavson LE, Sperelakis R, et al. Pharmacokinetics and safety of tiagabine in subjects with various degrees of hepatic function. Epilepsia 1997; 38: 445-51
99. Adkins JC, Noble S. Tiagabine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of epilepsy. Drugs 1998; 55: 437-60
100. So EL, Wolff D, Graves NM, et al. Pharmacokinetics of tiagabine as add-on therapy in patients taking enzyme-inducing antiepilepsy drugs. Epilepsy Res 1995; 22: 221-6
101. Williams J, Bialer M, Johannessen SI, et al. Interlaboratory variability in the quantification of new generation antiepileptic drugs based on external quality assessment data. Epilepsia 2003; 44: 40-5
102. Rowan AJ, Gustavson I, Shu V, et al. Dose concentration relationship in a multicenter tiagabine (Gabitril) trial [abstract]. Epilepsia 1997; 38 Suppl. 3: 40
103. Schmidt D, Gram L, Brodie M, et al. Tiagabine in the treatment of epilepsy: a clinical review with a guide for the prescribing physician. Epilepsy Res 2000; 41: 245-51
104. Langtry HD, Gillis JC, Davis R. Topiramate: a review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of epilepsy. Drugs 1997; 54: 752-73
105. Ferrari AR, Guerrini R, Gatti G, et al. Influence of dosage, age, and co-medication on plasma topiramate concentrations in children and adults with severe epilepsy and preliminary observations on correlations with clinical response. Ther Drug Monit 2003; 25: 700-8
106. Adin J, Gomez MC, Blanco Y, et al. Topiramate serum concentration-to-dose ratio: influence of age and concomitant antiepileptic drugs and monitoring implications. Ther Drug Monit 2004; 26: 251-7
107. Dahlin MG, Öhman IK. Age and antiepileptic drugs influence topiramate plasma levels in children. Pediatr Neurol 2004; 4: 248-53
108. Bialer M, Doose DR, Murthy B, et al. Pharmacokinetic interactions of topiramate. Clin Pharmacokinet 2004; 43: 763-80
109. Battino D, Croci D, Rossini A, et al. Topiramate pharmacokinetics in children and adults with epilepsy: a case-matched comparison based on therapeutic drug monitoring data. Clin Pharmacokinet 2005; 44: 407-16
110. Gisclon LG, Riffitts JM, Sica DA, et al. The pharmacokinetics of topiramate in subjects with renal impairment as compared to matched subjects with normal renal function [abstract]. Pharm Res 1993; 10 Suppl. 10: S397
111. Rosenberg WE, Liao S, Kramer LD, et al. Comparison of the steady-state pharmacokinetics of topiramate and valproate in patients with epilepsy during monotheraphy and concomitant therapy. Epilepsia 1997; 38: 324-33
112. Stephen LJ, Sills GJ, Brodie MJ. Topiramate in refractory epilepsy: a prospective observational study. Epilepsia 2000; 41: 977-80
113. Christensen J, Poulsen JH, Andreasen F, et al. Topiramate add-on treatment in refractory epilepsy patients: a randomised concentration controlled clinical trial [abstract]. Epilepsia 2001; 42 Suppl. 7: 178
114. Christensen J, Andreassen F, Poulsen JH, et al. Randomized, concentration-controlled trial of topiramate in refractory focal epilepsy. Neurology 2003; 61: 1210-8
115. Zanotta N, Raggi ME, Radice L, et al. Clinical experience with topiramate dosing and serum levels in patients with epilepsy. Seizure 2006 (Epub ahead of print)
116. Wheless JW, Nye JS, Wang S. Topiramate monotherapy: Plasma concentration vs therapeutic effect [abstract]. Epilepsia 2005; 46: 220
117. Preece NE, Jackson GD, Houseman JA, et al. Nuclear magnetic resonance detection of increased GABA in vigabatrin-treated rats in vivo. Epilepsia 1994; 35: 431-6
118. Schechter PJ. Clinical pharmacology of vigabatrin. Br J Clin Pharmacol 1989; 27: 19S-22
119. Patsalos PN, Duncan JS. The pharmacology and pharmacokinetics of vigabatrin. Rev Contemp Pharmacother 1995; 6: 447-56
120. Armijo JA, Cuadrado A, Bravo J, et al. Vigabatrin serum concentration to dosage ratio: influence of age and associated antiepileptic drugs. Ther Drug Monit 1997; 19: 491-8
121. Gatti G, Bartoli A, Marchiselli R, et al. Vigabatrin-induced decrease in serum concentration does not involve a change in phenytoin bioavailability. Br J Clin Pharmacol 1993; 36: 603-5
122. Schauf CL. Zonisamide enhances slow sodium inactivation in Myxicola. Brain Res 1987; 413: 185-8
123. Suzuki S, Kawakami K, Nishimura S, et al. Zonisamide blocks T-type calcium channel in cultured neurons of rat cerebral cortex. Epilepsy Res 1992; 12: 21-7
124. Mori A, Node Y, Packer I. The anticonvulsant zonisamide scavenges free radicals. Epilepsy Res 1998; 30: 153-8
125. Perucca E, Bialer M. The clinical pharmacokinetics of the newer antiepileptic drugs: focus on topiramate, zonisamide and tiagabine. Clin Pharmacokinet 1996; 31: 29-46
126. Seino M, Naruto S, Ito T, et al. Zonisamide. In: Levy RH, Mattson RH, Meldrum BS, editors. Antiepileptic drugs. 4th ed. New York: Raven Press, 1995: 1011-24
127. Miura H. Zonisamide monotherapy with once-daily dosing in children with cryptogenic localization-related epilepsies: clinical effects and pharmacokinetic studies. Seizure 2004; 13 Suppl. 1: S17-23
128. Peters DH, Sorkin EM. Zonisamide: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy. Drugs 1993; 45: 760-87
129. Levy RH, Ragueneau-Majlessi I, Brodie MJ, et al. Lack of clinically significant pharmacokinetic interactions between zonisamide and lamotrigine at steady state in patients with epilepsy. Ther Drug Monit 2005; 27: 193-8
130. Mimaki T. Clinical pharmacology and therapeutic drug monitoring of zonisamide. Ther Drug Monit 1998; 20: 593-7